According to a new report by IMARC Group, the global blood culture test market exhibited strong growth during 2015-2020. Looking forward, the market expects to grow at a CAGR of around 9% during 2021-2026.
A blood culture test is conducted to diagnose bacterial, fungal, and mycobacterial infections in the blood. It identifies various microorganisms in the blood sample and prevents the development of sepsis. The culture test helps in determining typical pathogens in the blood and possible ways to treat them. It utilizes blood culture media, assay kits, reagents, automated blood culture systems, and supporting laboratory equipment.
Global Blood Culture Test Market Trends
The sudden outbreak of COVID-19 has predominantly catalyzed the demand for blood culture tests to combat disease transmission. Several medical laboratories, diagnostic centers, and other healthcare facilities are widely adopting these tests to identify the presence of antibodies in the blood and isolate the infected individuals. The rising geriatric population, along with the growing consumer health concerns towards the high prevalence of infectious diseases, is further bolstering the market growth. The increasing healthcare expenditures, along with the growing number of R&D activities in the medical sector, are also proliferating the growth of the blood culture test market.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/blood-culture-test-market/requestsample
Global Blood Culture Test Market 2021-2026 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- Abbott Laboratories (ABT)
- Beckman Coulter ( BEC )
- BD (Becton, Dickinson and Company) (NYSE:BDX)
- BIOMERIEUX (BIM.PA)
- Bruker Corporation (BRKR)
- Cepheid (NASDAQ:CPHD). (Danaher Corporation)
- Luminex Corporation
- Merck Group
- Siemens Healthineers AG
- Roche Diagnostics
- T2 Biosystems, Inc. (TTOO)
- Thermo Fisher Scientific Inc. (NYSE: TMO)
For more information about this report visit: https://www.imarcgroup.com/blood-culture-test-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
